- Home
- CRVO vs TNYA Comparison
CRVO vs TNYA Comparison
Compare CRVO & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- TNYA
- Stock Information
- Founded
- CRVO 2001
- TNYA 2016
- Country
- CRVO United States
- TNYA United States
- Employees
- CRVO N/A
- TNYA N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- CRVO Health Care
- TNYA Health Care
- Exchange
- CRVO Nasdaq
- TNYA Nasdaq
- Market Cap
- CRVO 67.4M
- TNYA 73.8M
- IPO Year
- CRVO N/A
- TNYA 2021
- Fundamental
- Price
- CRVO $6.96
- TNYA $0.69
- Analyst Decision
- CRVO Strong Buy
- TNYA Strong Buy
- Analyst Count
- CRVO 7
- TNYA 5
- Target Price
- CRVO $19.33
- TNYA $8.60
- AVG Volume (30 Days)
- CRVO 162.5K
- TNYA 2.3M
- Earning Date
- CRVO 08-08-2025
- TNYA 08-07-2025
- Dividend Yield
- CRVO N/A
- TNYA N/A
- EPS Growth
- CRVO N/A
- TNYA N/A
- EPS
- CRVO N/A
- TNYA N/A
- Revenue
- CRVO $9,308,215.00
- TNYA N/A
- Revenue This Year
- CRVO N/A
- TNYA N/A
- Revenue Next Year
- CRVO N/A
- TNYA N/A
- P/E Ratio
- CRVO N/A
- TNYA N/A
- Revenue Growth
- CRVO 15.14
- TNYA N/A
- 52 Week Low
- CRVO $1.80
- TNYA $0.36
- 52 Week High
- CRVO $20.63
- TNYA $4.06
- Technical
- Relative Strength Index (RSI)
- CRVO 51.63
- TNYA 62.18
- Support Level
- CRVO $5.45
- TNYA $0.58
- Resistance Level
- CRVO $7.55
- TNYA $0.70
- Average True Range (ATR)
- CRVO 0.59
- TNYA 0.05
- MACD
- CRVO 0.14
- TNYA 0.00
- Stochastic Oscillator
- CRVO 75.71
- TNYA 93.66
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.